Presentations & Publications Corporate Presentation September 2021 Corporate Presentation September 20, 2021 PKU Clinical Program Update September 20, 2021 Publications Metabolic Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria Source Charbonneau et al, Communications Biology Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study Source Puurunen et al, Nature Metabolism Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nature Communications Source Nelson et al, Nature Communications An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Source Kurtz et al, Science Translational Medicine Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Source Isabella et al, Nature Biotechnology Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Source Kurtz et al, Clinical and Translational Science Immunology Metabolic modulation of tumours with engineered bacteria for immunotherapy Source Geiger et al, Nature Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Source Leventhal et al, Nature Communications Platform Developing a new class of engineered live bacterial therapeutics to treat human diseases Source Charbonneau et al, Nature Communications Engineering living therapeutics with synthetic biology Source Nature Reviews Drug Discovery Presentations and Posters Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine: SYNB8802 in Healthy Volunteers with Induced Dietary Hyperoxaluria: American Urological Association (AUA) Annual Meeting September 10, 2021 Synthetic Biotic Medicines for the Treatment of PKU: Global PKU Patient Conference September 10, 2021 Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU), Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting June 10, 2021 A Novel Human IL-22-Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease, Digestive Disease Week (DDW) May 23, 2021 Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting April 13, 2021 Intratumoral Injection of SYNB1891, a Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR) Annual Meeting April 10, 2021 Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020 Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, American Society of Nephrology (ASN) Kidney Week October 22, 2020 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer June 23, 2019 Email Alerts Contact IR RSS Feeds Print Page Email Page
Corporate Presentation September 2021 Corporate Presentation September 20, 2021 PKU Clinical Program Update September 20, 2021 Publications Metabolic Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria Source Charbonneau et al, Communications Biology Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study Source Puurunen et al, Nature Metabolism Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nature Communications Source Nelson et al, Nature Communications An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Source Kurtz et al, Science Translational Medicine Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Source Isabella et al, Nature Biotechnology Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Source Kurtz et al, Clinical and Translational Science Immunology Metabolic modulation of tumours with engineered bacteria for immunotherapy Source Geiger et al, Nature Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Source Leventhal et al, Nature Communications Platform Developing a new class of engineered live bacterial therapeutics to treat human diseases Source Charbonneau et al, Nature Communications Engineering living therapeutics with synthetic biology Source Nature Reviews Drug Discovery Presentations and Posters Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine: SYNB8802 in Healthy Volunteers with Induced Dietary Hyperoxaluria: American Urological Association (AUA) Annual Meeting September 10, 2021 Synthetic Biotic Medicines for the Treatment of PKU: Global PKU Patient Conference September 10, 2021 Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU), Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021 Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting June 10, 2021 A Novel Human IL-22-Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease, Digestive Disease Week (DDW) May 23, 2021 Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting April 13, 2021 Intratumoral Injection of SYNB1891, a Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR) Annual Meeting April 10, 2021 Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020 Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, American Society of Nephrology (ASN) Kidney Week October 22, 2020 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer June 23, 2019
Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria Source Charbonneau et al, Communications Biology
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study Source Puurunen et al, Nature Metabolism
Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip, Nature Communications Source Nelson et al, Nature Communications
An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Source Kurtz et al, Science Translational Medicine
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Source Isabella et al, Nature Biotechnology
Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Source Kurtz et al, Clinical and Translational Science
Metabolic modulation of tumours with engineered bacteria for immunotherapy Source Geiger et al, Nature
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Source Leventhal et al, Nature Communications
Developing a new class of engineered live bacterial therapeutics to treat human diseases Source Charbonneau et al, Nature Communications
Safety and Tolerability of an Oxalate-Consuming Synthetic Biotic Medicine: SYNB8802 in Healthy Volunteers with Induced Dietary Hyperoxaluria: American Urological Association (AUA) Annual Meeting September 10, 2021
Synthetic Biotic Medicines for the Treatment of PKU: Global PKU Patient Conference September 10, 2021
Synthetic Biology Approaches for the Optimization and Improvement of a Live Bacterial Therapeutic for the Treatment of Phenylketonuria (PKU), Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021
Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, Synthetic Biology: Engineering, Evolution & Design (SEED) Conference June 15, 2021
Development of a Synthetic Biotic, SYNB8802, for the treatment of Enteric Hyperoxaluria, American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting June 10, 2021
A Novel Human IL-22-Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease, Digestive Disease Week (DDW) May 23, 2021
Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers, American College of Medical Genetics (ACMG) Annual Meeting April 13, 2021
Intratumoral Injection of SYNB1891, a Synthetic Biotic medicine designed to activate the innate immune system, American Association for Cancer Research (AACR) Annual Meeting April 10, 2021
Development of a Synthetic Biotic for the Treatment of Enteric Hyperoxaluria, AlChE 3rd International Conference on Microbiome Engineering 2020 December 9, 2020
Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria, American Society of Nephrology (ASN) Kidney Week October 22, 2020
Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019